Status:
COMPLETED
Long-term Follow-up of Measles Antibodies
Lead Sponsor:
Bandim Health Project
Collaborating Sponsors:
Danish Council for Development Research
Novo Nordisk A/S
Conditions:
Measles
Eligibility:
All Genders
6-10 years
Phase:
PHASE4
Brief Summary
Few data exist on long-term persistence of measles antibodies after vaccination of West African infants. The data that do exist indicate that the antibody titres decline very rapidly. Our data would b...
Detailed Description
Objective To determine persistence of measles antibodies among children who received either one or two doses of Edmonston-Zagreb (EZ) or Schwarz (SW) measles vaccine. Background The World Health Orga...
Eligibility Criteria
Inclusion
- Children participating in the Two-dose trial (Non-Specific Effects of Standard Titre Measles Vaccination, Protocol ID: IC18-CT95-0011-Twodose1)
Exclusion
- Severe illness requiring hospitalisation
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
1960 Patients enrolled
Trial Details
Trial ID
NCT00168571
Start Date
March 1 2002
End Date
January 1 2007
Last Update
September 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bandim Health Project
Bissau, Apartado 861, Guinea-Bissau, 1004 Bissau Codex